Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2001 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: corticotropin

« Back to Dashboard
Corticotropin is the generic ingredient in six branded drugs marketed by Parkedale, Sanofi Aventis Us, Organics Lagrange, Watson Labs, Questcor Pharms, and Organon Usa Inc, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for corticotropin.

Summary for Generic Name: corticotropin

Tradenames:6
Patents:0
Applicants:6
NDAs:7
Drug Master File Entries: see list10
Formulation / Manufacturing:see details

Clinical Trials for: corticotropin

ACTHar in the Treatment of Lupus Nephritis
Status: Recruiting Condition: Lupus Nephritis

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Status: Active, not recruiting Condition: Diabetic Nephropathy

The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients
Status: Recruiting Condition: Rheumatoid Arthritis

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
Status: Completed Condition: Multiple Sclerosis (MS)

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.
Status: Recruiting Condition: Rheumatoid Arthritis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Questcor Pharms
H.P. ACTHAR GEL
corticotropin
Injectable; Injection008372-008Approved prior to Jan 1, 1982RXYes<disabled><disabled>
Organics Lagrange
CORTICOTROPIN
corticotropin
Injectable; Injection010831-001Approved prior to Jan 1, 1982RXNo<disabled><disabled>
Aventis
ACTHAR
corticotropin
Injectable; Injection007504-002Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
Parkedale
ACTH
corticotropin
Injectable; Injection008317-002Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
Organon
CORTROPHIN-ZINC
corticotropin-zinc hydroxide
Injectable; Injection009854-001Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc